2018
DOI: 10.1182/blood-2017-10-812495
|View full text |Cite
|
Sign up to set email alerts
|

Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes

Abstract: compared with treatment with placebo. 5 These results show that ruxolitinib reduces splenomegaly in patients with thalassemia and suggest that targeting EPO-EPOR-JAK2-STAT5 axis may limit the excessive proliferation of erythroid progenitors in spleen.Although there was an increase in hepcidin levels with ruxolitinib treatment in our study, no significant changes in either serum iron or ferritin levels were observed over time. However, increased levels of hepcidin may suggest that the handling of iron absorpti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
106
0
2

Year Published

2018
2018
2024
2024

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 86 publications
(110 citation statements)
references
References 8 publications
2
106
0
2
Order By: Relevance
“…Although surgical resection and radiotherapy are attempted for local control, metastases frequently occur, and in these cases, systemic chemotherapy with regimens of drugs used for lymphoma is often utilized (6)(7)(8). More options of medical intervention are needed to improve patients' survival time, which does not extend beyond 1 year (9,10). Although the etiology of HS is not yet clear, there is evidence suggesting a central role of the oncogenic RAS-RAF-MEK-ERK signaling pathway (11)(12)(13)(14)(15).…”
Section: Introductionmentioning
confidence: 99%
“…Although surgical resection and radiotherapy are attempted for local control, metastases frequently occur, and in these cases, systemic chemotherapy with regimens of drugs used for lymphoma is often utilized (6)(7)(8). More options of medical intervention are needed to improve patients' survival time, which does not extend beyond 1 year (9,10). Although the etiology of HS is not yet clear, there is evidence suggesting a central role of the oncogenic RAS-RAF-MEK-ERK signaling pathway (11)(12)(13)(14)(15).…”
Section: Introductionmentioning
confidence: 99%
“…The prognosis of histiocytic neoplasms is variable, and the natural course may be relatively benign and self-limiting in some cases, whereas in others it may be much more aggressive and life-threatening. [5][6][7] Most adult patients with histiocytic neoplasms receive empiric systemic immunosuppressive or cytotoxic therapies because of the lack of approved treatments. Recently, vemurafenib was approved by the US Food and Drug Administration for the treatment of BRAF-V600-mutant ECD.…”
mentioning
confidence: 99%
“…Since disease-specific therapies are lacking, systemic treatments include regimens for non-Hodgkin’s lymphoma or sarcoma. 3,4 Patients with histiocytic sarcoma and BRAF V600E mutations have been reported to have a response to vemurafenib. We describe a patient who had histiocytic sarcoma with an activating mutation in MAP2K1 who had a complete clinical response and a response on imaging to trametinib, a MAPK kinase (MEK) 1 and 2 inhibitor…”
Section: To the Editormentioning
confidence: 99%